Summer 2026 - Oncology Translational Bioinformatics Internship at Bristol-Myers Squibb

Winter Garden, Florida, United States

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, OncologyIndustries

Requirements

Master or PhD student enrolled in computational biology, bioinformatics, statistics, computer science, data science or related fields
Demonstrable hands-on experience with deep learning frameworks, particularly TensorFlow and PyTorch
Experience with neural network architectures, tree-based models and ensemble modeling methods

Responsibilities

Implement and adapt advanced deep learning frameworks for multi-modal biomarker discovery, customizing methodologies for clinical data requirements
Train and validate deep learning models on clinical trial datasets to identify predictive biomarkers for treatment response, incorporating both peripheral biomarkers and clinical variables
Develop model interpretability solutions to translate complex neural network predictions into clinically actionable and interpretable signatures
Conduct robust performance evaluations, benchmarking AI/ML models against existing biomarker approaches
Perform analysis and visualizations in a reproducible research framework, ensuring robust documentation of methodology and results
Deliver results and present findings to cross-functional teams for decision-making support

Skills

Bioinformatics

Machine Learning

Predictive Biomarkers

Clinical Data Analysis

Translational Informatics

Oncology Data

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free